State Street Corp Purchases 9,506 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

State Street Corp lifted its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 0.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,058,898 shares of the company’s stock after acquiring an additional 9,506 shares during the quarter. State Street Corp owned approximately 1.34% of Tenaya Therapeutics worth $2,044,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of TNYA. The Manufacturers Life Insurance Company boosted its stake in Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC bought a new position in shares of Tenaya Therapeutics in the second quarter valued at about $74,000. SG Americas Securities LLC acquired a new position in Tenaya Therapeutics during the 3rd quarter worth about $49,000. Panagora Asset Management Inc. bought a new stake in Tenaya Therapeutics during the 2nd quarter worth about $164,000. Finally, Walleye Capital LLC acquired a new stake in Tenaya Therapeutics in the 3rd quarter valued at about $134,000. 90.54% of the stock is currently owned by institutional investors.

Tenaya Therapeutics Stock Down 1.4 %

TNYA stock opened at $1.43 on Thursday. Tenaya Therapeutics, Inc. has a twelve month low of $0.99 and a twelve month high of $7.01. The business’s fifty day moving average is $2.39 and its 200-day moving average is $2.57. The company has a market cap of $113.29 million, a P/E ratio of -0.99 and a beta of 2.72.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. Research analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TNYA shares. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.